FDA notifies Amgen of misbranding of its biological product, Neulasta, due to false or misleading promotional communications about the product ’s benefit

The Food and Drug Administration (FDA) has issued an untitled letter to Amgen Inc. for the misbranding of its biological product, Neulasta (pegfilgrastim) injection, for subcutaneous use, resulting from a false or misleading promotional communication.

http://www.fda.gov/drugs/drug-safety-and-availability/fda-notifies-amgen-misbran...

Source: FDA Center for Drug Evaluation and Research - What's New - July 14, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Neulasta